Positive top-line results from the Phase III MARIPOSA study could help bring more choice for certain people with non-small cell lung cancer (NSCLC).
Johnson & Johnson’s (NYSE: JNJ) biotech business, Janssen, is testing Rybrevant (amivantamab-vmjw), in combination with lazertinib, as a first-line treatment.
J&J has been working on the development of lazertinib under the terms of a major license and collaboration agreement with South Korean pharma company Yuhan Corp (KS: 000100), since 2018.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze